Global Immunoglobulins Market: Industry Analysis and Forecast (2019-2026): By Product, Disease Type and Region.

Global Immunoglobulins Market was valued US$ XX Bn in 2018 and is expected to reach US$ 17.4 Bn by 2026, at an XX% CAGR of around during a forecast period. Global Immunoglobulins Market To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Immunoglobulins are glycoproteins made in the response to an immunogen by plasma cells and purpose as antibodies. Overall purposes of immunoglobulins are antigen binding and effector functions. Immunoglobulins bind exactly to antigenic determinants and prevent the host from infections. The report contains a detailed list of factors that will drive and growth and restraint of the immunoglobulin’s market. Manufacturers are more focused on innovations to upsurge the applicability of immunoglobulins in other indications. Biotechnology companies work closely with research organizations and academic institutes for the development of immunoglobulins by alternative means. In Developed economies, demand for immunoglobulins is increasing because of high awareness and others part of the market, manufacturers are mainly focused on marketing to increase awareness among the end-user. Immunoglobulins market have a presence of many regional players which have a huge market share in emerging countries operating at the regional or country level. However, stringent government regulations related to immunoglobulin products and high risk of side effects, on the consumption of immunoglobulin are other factors hindering the growth of the global immunoglobulins market to a certain extent. The report offers a brief analysis of the major regions in the immunoglobulins market, namely, Asia-Pacific, Europe, North America, South America, and the Middle East & Africa. The North America immunoglobulins market was worth USD XX Mn in 2018. Immunoglobulin is the most popular treatment available for many immune disorders. Additionally, the number of patients in the region is growing. These factors are expected to contribute to market growth. The intravenous segment accounted for the highest revenue in 2018 and expected to maintain its dominance during the forecast period. High bioavailability of immunoglobulins and rapid absorption rate existing by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery immunoglobulins market globally. The report offers a recent development in the global market for immunoglobulins like in 2017 Grifols, S.A was prominent the global immunoglobulins market. Grifols owns a diverse product portfolio and that is aiding the organization to have major gains. The company holds a major share in many regional markets also. The objective of the report is to present comprehensive analysis of Global Immunoglobulins Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Immunoglobulins Market dynamics, structure by analyzing the market segments, and project the Global Immunoglobulins Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Immunoglobulins Market make the report investor’s guide.

Scope of the Global Immunoglobulins Market: Inquire before buying

Global Immunoglobulins Market, By Application

• Hypogammaglobulinemia • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) • Immunodeficiency Disease • Myasthenia Gravis • Multifocal Motor Neuropathy • Idiopathic Thrombocytopenic Purpura (ITP) • Inflammatory Myopathies • Specific Antibody Deficiency • Guillain‐Barré Syndrome • Others

Global Immunoglobulins Market, By Product

• IgG • IgA • IgM • IgE • IgD

Global Immunoglobulins Market, By Mode of Delivery

• Intravenous o 5% Concentration o 10% Concentration o Others • Subcutaneous o 16.5% Concentration o 20% Concentration o Others

Global Immunoglobulins Market, By Region

• North America • Asia Pacific • Europe • Middle East & Africa • South America

Key players operating in the Global Immunoglobulins Market

• Shire (Takeda Pharmaceutical Company Limited) • CSL Behring • Grifols, S.A. • Kedrion S.p.A • Octapharma • Bio Products Laboratory Ltd. • Biotest AG • China Biologic Products Holdings, Inc. • LFB SA • Shanghai RAAS Blood Products Co., Ltd. • Amgen Inc • AbbVie Inc. • Gilead Sciences • Novartis AG • Johnson & Johnson • Merck & Co., Inc • F. Hoffmann-La Roche Ltd
Global Immunoglobulins Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Immunoglobulins Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Immunoglobulins Market Analysis and Forecast 6.1. Global Immunoglobulins Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Immunoglobulins Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Immunoglobulins Market Value Share Analysis, By Application 7.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Application 7.5. Global Immunoglobulins Market Analysis, By Application 7.6. Global Immunoglobulins Market Attractiveness Analysis, By Application 8. Global Immunoglobulins Market Analysis and Forecast, By Product 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Immunoglobulins Market Value Share Analysis, By Product 8.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Product 8.5. Global Immunoglobulins Market Analysis, By Product 8.6. Global Immunoglobulins Market Attractiveness Analysis, By Product 9. Global Immunoglobulins Market Analysis and Forecast, By Mode of Delivery 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Immunoglobulins Market Value Share Analysis, By Mode of Delivery 9.4. Global Immunoglobulins Market Size (US$ Bn) Forecast, By Mode of Delivery 9.5. Global Immunoglobulins Market Analysis, By Mode of Delivery 9.6. Global Immunoglobulins Market Attractiveness Analysis, By Mode of Delivery 10. Global Immunoglobulins Market Analysis, by Region 10.1. Global Immunoglobulins Market Value Share Analysis, by Region 10.2. Global Immunoglobulins Market Size (US$ Bn) Forecast, by Region 10.3. Global Immunoglobulins Market Attractiveness Analysis, by Region 11. North America Immunoglobulins Market Analysis 11.1. Key Findings 11.2. North America Immunoglobulins Market Overview 11.3. North America Immunoglobulins Market Value Share Analysis, By Application 11.4. North America Immunoglobulins Market Forecast, By Application 11.4.1. Hypogammaglobulinemia 11.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 11.4.3. Immunodeficiency Disease 11.4.4. Myasthenia Gravis 11.4.5. Multifocal Motor Neuropathy 11.4.6. Idiopathic Thrombocytopenic Purpura (ITP) 11.4.7. Inflammatory Myopathies 11.4.8. Specific Antibody Deficiency 11.4.9. Guillain-Barré Syndrome 11.4.10. Others 11.5. North America Immunoglobulins Market Value Share Analysis, By Product 11.6. North America Immunoglobulins Market Forecast, By Product 11.6.1. IgG 11.6.2. IgA 11.6.3. IgM 11.6.4. IgE 11.6.5. IgD 11.7. North America Immunoglobulins Market Value Share Analysis, By Mode of Delivery 11.8. North America Immunoglobulins Market Forecast, By Mode of Delivery 11.8.1. Intravenous 11.8.1.1. 5% Concentration 11.8.1.2. 10% Concentration 11.8.1.3. Others 11.8.2. Subcutaneous 11.8.2.1. 16.5% Concentration 11.8.2.2. 20% Concentration 11.8.2.3. Others 11.9. North America Immunoglobulins Market Value Share Analysis, by Country 11.10. North America Immunoglobulins Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Immunoglobulins Market Analysis, by Country 11.12. U.S. Immunoglobulins Market Forecast, By Application 11.12.1. Hypogammaglobulinemia 11.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 11.12.3. Immunodeficiency Disease 11.12.4. Myasthenia Gravis 11.12.5. Multifocal Motor Neuropathy 11.12.6. Idiopathic Thrombocytopenic Purpura (ITP) 11.12.7. Inflammatory Myopathies 11.12.8. Specific Antibody Deficiency 11.12.9. Guillain-Barré Syndrome 11.12.10. Others 11.13. U.S. Immunoglobulins Market Forecast, By Product 11.13.1. IgG 11.13.2. IgA 11.13.3. IgM 11.13.4. IgE 11.13.5. IgD 11.14. U.S. Immunoglobulins Market Forecast, By Mode of Delivery 11.14.1. Intravenous 11.14.1.1. 5% Concentration 11.14.1.2. 10% Concentration 11.14.1.3. Others 11.14.2. Subcutaneous 11.14.2.1. 16.5% Concentration 11.14.2.2. 20% Concentration 11.14.2.3. Others 11.15. Canada Immunoglobulins Market Forecast, By Application 11.15.1. Hypogammaglobulinemia 11.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 11.15.3. Immunodeficiency Disease 11.15.4. Myasthenia Gravis 11.15.5. Multifocal Motor Neuropathy 11.15.6. Idiopathic Thrombocytopenic Purpura (ITP) 11.15.7. Inflammatory Myopathies 11.15.8. Specific Antibody Deficiency 11.15.9. Guillain-Barré Syndrome 11.15.10. Others 11.16. Steel Canada Immunoglobulins Market Forecast, By Product 11.16.1. IgG 11.16.2. IgA 11.16.3. IgM 11.16.4. IgE 11.16.5. IgD 11.17. Canada Immunoglobulins Market Forecast, By Mode of Delivery 11.17.1. Intravenous 11.17.1.1. 5% Concentration 11.17.1.2. 10% Concentration 11.17.1.3. Others 11.17.2. Subcutaneous 11.17.2.1. 16.5% Concentration 11.17.2.2. 20% Concentration 11.17.2.3. Others 11.18. North America Immunoglobulins Market Attractiveness Analysis 11.18.1. By Application 11.18.2. By Product 11.18.3. By Mode of Delivery 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Immunoglobulins Market Analysis 12.1. Key Findings 12.2. Europe Immunoglobulins Market Overview 12.3. Europe Immunoglobulins Market Value Share Analysis, By Application 12.4. Europe Immunoglobulins Market Forecast, By Application 12.4.1. Hypogammaglobulinemia 12.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.4.3. Immunodeficiency Disease 12.4.4. Myasthenia Gravis 12.4.5. Multifocal Motor Neuropathy 12.4.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.4.7. Inflammatory Myopathies 12.4.8. Specific Antibody Deficiency 12.4.9. Guillain-Barré Syndrome 12.4.10. Others 12.5. Europe Immunoglobulins Market Value Share Analysis, By Product 12.6. Europe Immunoglobulins Market Forecast, By Product 12.6.1. IgG 12.6.2. IgA 12.6.3. IgM 12.6.4. IgE 12.6.5. IgD 12.7. Europe Immunoglobulins Market Value Share Analysis, By Mode of Delivery 12.8. Europe Immunoglobulins Market Forecast, By Mode of Delivery 12.8.1. Intravenous 12.8.1.1. 5% Concentration 12.8.1.2. 10% Concentration 12.8.1.3. Others 12.8.2. Subcutaneous 12.8.2.1. 16.5% Concentration 12.8.2.2. 20% Concentration 12.8.2.3. Others 12.9. Europe Immunoglobulins Market Value Share Analysis, by Country 12.10. Europe Immunoglobulins Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Immunoglobulins Market Analysis, by Country 12.12. Germany Immunoglobulins Market Forecast, By Application 12.12.1. Hypogammaglobulinemia 12.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.12.3. Immunodeficiency Disease 12.12.4. Myasthenia Gravis 12.12.5. Multifocal Motor Neuropathy 12.12.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.12.7. Inflammatory Myopathies 12.12.8. Specific Antibody Deficiency 12.12.9. Guillain-Barré Syndrome 12.12.10. Others 12.13. Germany Immunoglobulins Market Forecast, By Product 12.13.1. IgG 12.13.2. IgA 12.13.3. IgM 12.13.4. IgE 12.13.5. IgD 12.14. Germany Immunoglobulins Market Forecast, By Mode of Delivery 12.14.1. Intravenous 12.14.1.1. 5% Concentration 12.14.1.2. 10% Concentration 12.14.1.3. Others 12.14.2. Subcutaneous 12.14.2.1. 16.5% Concentration 12.14.2.2. 20% Concentration 12.14.2.3. Others 12.15. U.K. Immunoglobulins Market Forecast, By Application 12.15.1. Hypogammaglobulinemia 12.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.15.3. Immunodeficiency Disease 12.15.4. Myasthenia Gravis 12.15.5. Multifocal Motor Neuropathy 12.15.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.15.7. Inflammatory Myopathies 12.15.8. Specific Antibody Deficiency 12.15.9. Guillain-Barré Syndrome 12.15.10. Others 12.16. U.K. Immunoglobulins Market Forecast, By Product 12.16.1. IgG 12.16.2. IgA 12.16.3. IgM 12.16.4. IgE 12.16.5. IgD 12.17. U.K. Immunoglobulins Market Forecast, By Mode of Delivery 12.17.1. Intravenous 12.17.1.1. 5% Concentration 12.17.1.2. 10% Concentration 12.17.1.3. Others 12.17.2. Subcutaneous 12.17.2.1. 16.5% Concentration 12.17.2.2. 20% Concentration 12.17.2.3. Others 12.18. France Immunoglobulins Market Forecast, By Application 12.18.1. Hypogammaglobulinemia 12.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.18.3. Immunodeficiency Disease 12.18.4. Myasthenia Gravis 12.18.5. Multifocal Motor Neuropathy 12.18.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.18.7. Inflammatory Myopathies 12.18.8. Specific Antibody Deficiency 12.18.9. Guillain-Barré Syndrome 12.18.10. Others 12.19. France Immunoglobulins Market Forecast, By Product 12.19.1. IgG 12.19.2. IgA 12.19.3. IgM 12.19.4. IgE 12.19.5. IgD 12.20. France Immunoglobulins Market Forecast, By Mode of Delivery 12.20.1. Intravenous 12.20.1.1. 5% Concentration 12.20.1.2. 10% Concentration 12.20.1.3. Others 12.20.2. Subcutaneous 12.20.2.1. 16.5% Concentration 12.20.2.2. 20% Concentration 12.20.2.3. Others 12.21. Italy Immunoglobulins Market Forecast, By Application 12.21.1. Hypogammaglobulinemia 12.21.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.21.3. Immunodeficiency Disease 12.21.4. Myasthenia Gravis 12.21.5. Multifocal Motor Neuropathy 12.21.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.21.7. Inflammatory Myopathies 12.21.8. Specific Antibody Deficiency 12.21.9. Guillain-Barré Syndrome 12.21.10. Others 12.22. Italy Immunoglobulins Market Forecast, By Product 12.22.1. IgG 12.22.2. IgA 12.22.3. IgM 12.22.4. IgE 12.22.5. IgD 12.23. Italy Immunoglobulins Market Forecast, By Mode of Delivery 12.23.1. Intravenous 12.23.1.1. 5% Concentration 12.23.1.2. 10% Concentration 12.23.1.3. Others 12.23.2. Subcutaneous 12.23.2.1. 16.5% Concentration 12.23.2.2. 20% Concentration 12.23.2.3. Others 12.24. Spain Immunoglobulins Market Forecast, By Application 12.24.1. Hypogammaglobulinemia 12.24.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.24.3. Immunodeficiency Disease 12.24.4. Myasthenia Gravis 12.24.5. Multifocal Motor Neuropathy 12.24.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.24.7. Inflammatory Myopathies 12.24.8. Specific Antibody Deficiency 12.24.9. Guillain-Barré Syndrome 12.24.10. Others 12.25. Spain Immunoglobulins Market Forecast, By Product 12.25.1. IgG 12.25.2. IgA 12.25.3. IgM 12.25.4. IgE 12.25.5. IgD 12.26. Spain Immunoglobulins Market Forecast, By Mode of Delivery 12.26.1. Intravenous 12.26.1.1. 5% Concentration 12.26.1.2. 10% Concentration 12.26.1.3. Others 12.26.2. Subcutaneous 12.26.2.1. 16.5% Concentration 12.26.2.2. 20% Concentration 12.26.2.3. Others 12.27. Rest of Europe Immunoglobulins Market Forecast, By Application 12.27.1. Hypogammaglobulinemia 12.27.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 12.27.3. Immunodeficiency Disease 12.27.4. Myasthenia Gravis 12.27.5. Multifocal Motor Neuropathy 12.27.6. Idiopathic Thrombocytopenic Purpura (ITP) 12.27.7. Inflammatory Myopathies 12.27.8. Specific Antibody Deficiency 12.27.9. Guillain-Barré Syndrome 12.27.10. Others 12.28. Rest of Europe Immunoglobulins Market Forecast, By Product 12.28.1. IgG 12.28.2. IgA 12.28.3. IgM 12.28.4. IgE 12.28.5. IgD 12.29. Rest Of Europe Immunoglobulins Market Forecast, By Mode of Delivery 12.29.1. Intravenous 12.29.1.1. 5% Concentration 12.29.1.2. 10% Concentration 12.29.1.3. Others 12.29.2. Subcutaneous 12.29.2.1. 16.5% Concentration 12.29.2.2. 20% Concentration 12.29.2.3. Others 12.30. Europe Immunoglobulins Market Attractiveness Analysis 12.30.1. By Application 12.30.2. By Product 12.30.3. By Mode of Delivery 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Immunoglobulins Market Analysis 13.1. Key Findings 13.2. Asia Pacific Immunoglobulins Market Overview 13.3. Asia Pacific Immunoglobulins Market Value Share Analysis, By Application 13.4. Asia Pacific Immunoglobulins Market Forecast, By Application 13.4.1. Hypogammaglobulinemia 13.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.4.3. Immunodeficiency Disease 13.4.4. Myasthenia Gravis 13.4.5. Multifocal Motor Neuropathy 13.4.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.4.7. Inflammatory Myopathies 13.4.8. Specific Antibody Deficiency 13.4.9. Guillain-Barré Syndrome 13.4.10. Others 13.5. Asia Pacific Immunoglobulins Market Value Share Analysis, By Product 13.6. Asia Pacific Immunoglobulins Market Forecast, By Product 13.6.1. IgG 13.6.2. IgA 13.6.3. IgM 13.6.4. IgE 13.6.5. IgD 13.7. Asia Pacific Immunoglobulins Market Value Share Analysis, By Mode of Delivery 13.8. Asia Pacific Immunoglobulins Market Forecast, By Mode of Delivery 13.8.1. Intravenous 13.8.1.1. 5% Concentration 13.8.1.2. 10% Concentration 13.8.1.3. Others 13.8.2. Subcutaneous 13.8.2.1. 16.5% Concentration 13.8.2.2. 20% Concentration 13.8.2.3. Others 13.9. Asia Pacific Immunoglobulins Market Value Share Analysis, by Country 13.10. Asia Pacific Immunoglobulins Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Immunoglobulins Market Analysis, by Country 13.12. China Immunoglobulins Market Forecast, By Application 13.12.1. Hypogammaglobulinemia 13.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.12.3. Immunodeficiency Disease 13.12.4. Myasthenia Gravis 13.12.5. Multifocal Motor Neuropathy 13.12.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.12.7. Inflammatory Myopathies 13.12.8. Specific Antibody Deficiency 13.12.9. Guillain-Barré Syndrome 13.12.10. Others 13.13. China Immunoglobulins Market Forecast, By Product 13.13.1. IgG 13.13.2. IgA 13.13.3. IgM 13.13.4. IgE 13.13.5. IgD 13.14. China Immunoglobulins Market Forecast, By Mode of Delivery 13.14.1. Intravenous 13.14.1.1. 5% Concentration 13.14.1.2. 10% Concentration 13.14.1.3. Others 13.14.2. Subcutaneous 13.14.2.1. 16.5% Concentration 13.14.2.2. 20% Concentration 13.14.2.3. Others 13.15. India Immunoglobulins Market Forecast, By Application 13.15.1. Hypogammaglobulinemia 13.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.15.3. Immunodeficiency Disease 13.15.4. Myasthenia Gravis 13.15.5. Multifocal Motor Neuropathy 13.15.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.15.7. Inflammatory Myopathies 13.15.8. Specific Antibody Deficiency 13.15.9. Guillain-Barré Syndrome 13.15.10. Others 13.16. India Immunoglobulins Market Forecast, By Product 13.16.1. IgG 13.16.2. IgA 13.16.3. IgM 13.16.4. IgE 13.16.5. IgD 13.17. India Immunoglobulins Market Forecast, By Mode of Delivery 13.17.1. Intravenous 13.17.1.1. 5% Concentration 13.17.1.2. 10% Concentration 13.17.1.3. Others 13.17.2. Subcutaneous 13.17.2.1. 16.5% Concentration 13.17.2.2. 20% Concentration 13.17.2.3. Others 13.18. Japan Immunoglobulins Market Forecast, By Application 13.18.1. Hypogammaglobulinemia 13.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.18.3. Immunodeficiency Disease 13.18.4. Myasthenia Gravis 13.18.5. Multifocal Motor Neuropathy 13.18.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.18.7. Inflammatory Myopathies 13.18.8. Specific Antibody Deficiency 13.18.9. Guillain-Barré Syndrome 13.18.10. Others 13.19. Japan Immunoglobulins Market Forecast, By Product 13.19.1. IgG 13.19.2. IgA 13.19.3. IgM 13.19.4. IgE 13.19.5. IgD 13.20. Japan Immunoglobulins Market Forecast, By Mode of Delivery 13.20.1. Intravenous 13.20.1.1. 5% Concentration 13.20.1.2. 10% Concentration 13.20.1.3. Others 13.20.2. Subcutaneous 13.20.2.1. 16.5% Concentration 13.20.2.2. 20% Concentration 13.20.2.3. Others 13.21. ASEAN Immunoglobulins Market Forecast, By Application 13.21.1. Hypogammaglobulinemia 13.21.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.21.3. Immunodeficiency Disease 13.21.4. Myasthenia Gravis 13.21.5. Multifocal Motor Neuropathy 13.21.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.21.7. Inflammatory Myopathies 13.21.8. Specific Antibody Deficiency 13.21.9. Guillain-Barré Syndrome 13.21.10. Others 13.22. ASEAN Immunoglobulins Market Forecast, By Product 13.22.1. IgG 13.22.2. IgA 13.22.3. IgM 13.22.4. IgE 13.22.5. IgD 13.23. ASEAN Immunoglobulins Market Forecast, By Mode of Delivery 13.23.1. Intravenous 13.23.1.1. 5% Concentration 13.23.1.2. 10% Concentration 13.23.1.3. Others 13.23.2. Subcutaneous 13.23.2.1. 16.5% Concentration 13.23.2.2. 20% Concentration 13.23.2.3. Others 13.24. Rest of Asia Pacific Immunoglobulins Market Forecast, By Application 13.24.1. Hypogammaglobulinemia 13.24.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 13.24.3. Immunodeficiency Disease 13.24.4. Myasthenia Gravis 13.24.5. Multifocal Motor Neuropathy 13.24.6. Idiopathic Thrombocytopenic Purpura (ITP) 13.24.7. Inflammatory Myopathies 13.24.8. Specific Antibody Deficiency 13.24.9. Guillain-Barré Syndrome 13.24.10. Others 13.25. Rest of Asia Pacific Immunoglobulins Market Forecast, By Product 13.25.1. IgG 13.25.2. IgA 13.25.3. IgM 13.25.4. IgE 13.25.5. IgD 13.26. Rest of Asia Pacific Immunoglobulins Market Forecast, By Mode of Delivery 13.26.1. Intravenous 13.26.1.1. 5% Concentration 13.26.1.2. 10% Concentration 13.26.1.3. Others 13.26.2. Subcutaneous 13.26.2.1. 16.5% Concentration 13.26.2.2. 20% Concentration 13.26.2.3. Others 13.27. Asia Pacific Immunoglobulins Market Attractiveness Analysis 13.27.1. By Application 13.27.2. By Product 13.27.3. By Mode of Delivery 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Immunoglobulins Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Immunoglobulins Market Overview 14.3. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Application 14.4. Middle East & Africa Immunoglobulins Market Forecast, By Application 14.4.1. Hypogammaglobulinemia 14.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 14.4.3. Immunodeficiency Disease 14.4.4. Myasthenia Gravis 14.4.5. Multifocal Motor Neuropathy 14.4.6. Idiopathic Thrombocytopenic Purpura (ITP) 14.4.7. Inflammatory Myopathies 14.4.8. Specific Antibody Deficiency 14.4.9. Guillain-Barré Syndrome 14.4.10. Others 14.5. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Product 14.6. Middle East & Africa Immunoglobulins Market Forecast, By Product 14.6.1. IgG 14.6.2. IgA 14.6.3. IgM 14.6.4. IgE 14.6.5. IgD 14.7. Middle East & Africa Immunoglobulins Market Value Share Analysis, By Mode of Delivery 14.8. Middle East & Africa Immunoglobulins Market Forecast, By Mode of Delivery 14.8.1. Intravenous 14.8.1.1. 5% Concentration 14.8.1.2. 10% Concentration 14.8.1.3. Others 14.8.2. Subcutaneous 14.8.2.1. 16.5% Concentration 14.8.2.2. 20% Concentration 14.8.2.3. Others 14.9. Middle East & Africa Immunoglobulins Market Value Share Analysis, by Country 14.10. Middle East & Africa Immunoglobulins Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Immunoglobulins Market Analysis, by Country 14.12. GCC Immunoglobulins Market Forecast, By Application 14.12.1. Hypogammaglobulinemia 14.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 14.12.3. Immunodeficiency Disease 14.12.4. Myasthenia Gravis 14.12.5. Multifocal Motor Neuropathy 14.12.6. Idiopathic Thrombocytopenic Purpura (ITP) 14.12.7. Inflammatory Myopathies 14.12.8. Specific Antibody Deficiency 14.12.9. Guillain-Barré Syndrome 14.12.10. Others 14.13. GCC Immunoglobulins Market Forecast, By Product 14.13.1. IgG 14.13.2. IgA 14.13.3. IgM 14.13.4. IgE 14.13.5. IgD 14.14. GCC Immunoglobulins Market Forecast, By Mode of Delivery 14.14.1. Intravenous 14.14.1.1. 5% Concentration 14.14.1.2. 10% Concentration 14.14.1.3. Others 14.14.2. Subcutaneous 14.14.2.1. 16.5% Concentration 14.14.2.2. 20% Concentration 14.14.2.3. Others 14.15. South Africa Immunoglobulins Market Forecast, By Application 14.15.1. Hypogammaglobulinemia 14.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 14.15.3. Immunodeficiency Disease 14.15.4. Myasthenia Gravis 14.15.5. Multifocal Motor Neuropathy 14.15.6. Idiopathic Thrombocytopenic Purpura (ITP) 14.15.7. Inflammatory Myopathies 14.15.8. Specific Antibody Deficiency 14.15.9. Guillain-Barré Syndrome 14.15.10. Others 14.16. South Africa Immunoglobulins Market Forecast, By Product 14.16.1. IgG 14.16.2. IgA 14.16.3. IgM 14.16.4. IgE 14.16.5. IgD 14.17. South Africa Immunoglobulins Market Forecast, By Mode of Delivery 14.17.1. Intravenous 14.17.1.1. 5% Concentration 14.17.1.2. 10% Concentration 14.17.1.3. Others 14.17.2. Subcutaneous 14.17.2.1. 16.5% Concentration 14.17.2.2. 20% Concentration 14.17.2.3. Others 14.18. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Application 14.18.1. Hypogammaglobulinemia 14.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 14.18.3. Immunodeficiency Disease 14.18.4. Myasthenia Gravis 14.18.5. Multifocal Motor Neuropathy 14.18.6. Idiopathic Thrombocytopenic Purpura (ITP) 14.18.7. Inflammatory Myopathies 14.18.8. Specific Antibody Deficiency 14.18.9. Guillain-Barré Syndrome 14.18.10. Others 14.19. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Product 14.19.1. IgG 14.19.2. IgA 14.19.3. IgM 14.19.4. IgE 14.19.5. IgD 14.20. Rest of Middle East & Africa Immunoglobulins Market Forecast, By Mode of Delivery 14.20.1. Intravenous 14.20.1.1. 5% Concentration 14.20.1.2. 10% Concentration 14.20.1.3. Others 14.20.2. Subcutaneous 14.20.2.1. 16.5% Concentration 14.20.2.2. 20% Concentration 14.20.2.3. Others 14.21. Middle East & Africa Immunoglobulins Market Attractiveness Analysis 14.21.1. By Application 14.21.2. By Product 14.21.3. By Mode of Delivery 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Immunoglobulins Market Analysis 15.1. Key Findings 15.2. South America Immunoglobulins Market Overview 15.3. South America Immunoglobulins Market Value Share Analysis, By Application 15.4. South America Immunoglobulins Market Forecast, By Application 15.4.1. Hypogammaglobulinemia 15.4.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 15.4.3. Immunodeficiency Disease 15.4.4. Myasthenia Gravis 15.4.5. Multifocal Motor Neuropathy 15.4.6. Idiopathic Thrombocytopenic Purpura (ITP) 15.4.7. Inflammatory Myopathies 15.4.8. Specific Antibody Deficiency 15.4.9. Guillain-Barré Syndrome 15.4.10. Others 15.5. South America Immunoglobulins Market Value Share Analysis, By Product 15.6. South America Immunoglobulins Market Forecast, By Product 15.6.1. IgG 15.6.2. IgA 15.6.3. IgM 15.6.4. IgE 15.6.5. IgD 15.7. South America Immunoglobulins Market Value Share Analysis, By Mode of Delivery 15.8. South America Immunoglobulins Market Forecast, By Mode of Delivery 15.8.1. Intravenous 15.8.1.1. 5% Concentration 15.8.1.2. 10% Concentration 15.8.1.3. Others 15.8.2. Subcutaneous 15.8.2.1. 16.5% Concentration 15.8.2.2. 20% Concentration 15.8.2.3. Others 15.9. South America Immunoglobulins Market Value Share Analysis, by Country 15.10. South America Immunoglobulins Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Immunoglobulins Market Analysis, by Country 15.12. Brazil Immunoglobulins Market Forecast, By Application 15.12.1. Hypogammaglobulinemia 15.12.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 15.12.3. Immunodeficiency Disease 15.12.4. Myasthenia Gravis 15.12.5. Multifocal Motor Neuropathy 15.12.6. Idiopathic Thrombocytopenic Purpura (ITP) 15.12.7. Inflammatory Myopathies 15.12.8. Specific Antibody Deficiency 15.12.9. Guillain-Barré Syndrome 15.12.10. Others 15.13. Brazil Immunoglobulins Market Forecast, By Product 15.13.1. IgG 15.13.2. IgA 15.13.3. IgM 15.13.4. IgE 15.13.5. IgD 15.14. Brazil Immunoglobulins Market Forecast, By Mode of Delivery 15.14.1. Intravenous 15.14.1.1. 5% Concentration 15.14.1.2. 10% Concentration 15.14.1.3. Others 15.14.2. Subcutaneous 15.14.2.1. 16.5% Concentration 15.14.2.2. 20% Concentration 15.14.2.3. Others 15.15. Mexico Immunoglobulins Market Forecast, By Application 15.15.1. Hypogammaglobulinemia 15.15.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 15.15.3. Immunodeficiency Disease 15.15.4. Myasthenia Gravis 15.15.5. Multifocal Motor Neuropathy 15.15.6. Idiopathic Thrombocytopenic Purpura (ITP) 15.15.7. Inflammatory Myopathies 15.15.8. Specific Antibody Deficiency 15.15.9. Guillain-Barré Syndrome 15.15.10. Others 15.16. Mexico Immunoglobulins Market Forecast, By Product 15.16.1. IgG 15.16.2. IgA 15.16.3. IgM 15.16.4. IgE 15.16.5. IgD 15.17. Mexico Immunoglobulins Market Forecast, By Mode of Delivery 15.17.1. Intravenous 15.17.1.1. 5% Concentration 15.17.1.2. 10% Concentration 15.17.1.3. Others 15.17.2. Subcutaneous 15.17.2.1. 16.5% Concentration 15.17.2.2. 20% Concentration 15.17.2.3. Others 15.18. Rest of South America Immunoglobulins Market Forecast, By Application 15.18.1. Hypogammaglobulinemia 15.18.2. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 15.18.3. Immunodeficiency Disease 15.18.4. Myasthenia Gravis 15.18.5. Multifocal Motor Neuropathy 15.18.6. Idiopathic Thrombocytopenic Purpura (ITP) 15.18.7. Inflammatory Myopathies 15.18.8. Specific Antibody Deficiency 15.18.9. Guillain-Barré Syndrome 15.18.10. Others 15.19. Rest of South America Immunoglobulins Market Forecast, By Product 15.19.1. IgG 15.19.2. IgA 15.19.3. IgM 15.19.4. IgE 15.19.5. IgD 15.20. Rest of South America Immunoglobulins Market Forecast, By Mode of Delivery 15.20.1. Intravenous 15.20.1.1. 5% Concentration 15.20.1.2. 10% Concentration 15.20.1.3. Others 15.20.2. Subcutaneous 15.20.2.1. 16.5% Concentration 15.20.2.2. 20% Concentration 15.20.2.3. Others 15.21. South America Immunoglobulins Market Attractiveness Analysis 15.21.1. By Application 15.21.2. By Product 15.21.3. By Mode of Delivery 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Shire (Takeda Pharmaceutical Company Limited) 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. CSL Behring 16.3.3. Grifols, S.A. 16.3.4. Kedrion S.p.A 16.3.5. Octapharma 16.3.6. Bio Products Laboratory Ltd. 16.3.7. Biotest AG 16.3.8. China Biologic Products Holdings, Inc. 16.3.9. LFB SA 16.3.10. Shanghai RAAS Blood Products Co., Ltd. 16.3.11. Amgen Inc 16.3.12. AbbVie Inc. 16.3.13. Gilead Sciences 16.3.14. Novartis AG 16.3.15. Johnson & Johnson 16.3.16. Merck & Co., Inc 16.3.17. F. Hoffmann-La Roche Ltd 17. Primary Key Insights

About This Report

Report ID 36199
Category Healthcare
Published Date Nov 2019
Updated Date Dec 2020
Contact Us